DEVICE AND PROCEDURE FOR THE PROOF OF MOLECULAR RECIPROCAL EFFECTS

Pyridinone derivatives and their use as selective ALK-2 inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Assays

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative for the presence and/or amount of the target molecules, a microfluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the microfluidic network.

Formulation comprising benzothiazolone compound

The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5- hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.

Use of fused imidazole derivatives to mediate CCR3 related conditions

The use of compound of formula (I) in the preparation of a medicament , e.g, for the treatment of condition mediated by CCR 3.

VORRICHTUNG UND VERFAHREN ZUM NACHWEIS VON MOLEKULAREN WECHSELWIRKUNGEN

BLISTER PACK WITH RADIO FREQUENCY IDENTIFICATION MECHANISM AS WELL AS PROCEDURE FOR THEIR PRODUCTION

DEVICE FOR THE MOUNTING PLATE OF A SUBSTANCE LIBRARY CARRIER

Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions

The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R, R, Ar, A and B are defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. 2. A compound of formula (I) in free form or in pharmaceutically acceptable salt form according to claim 1 ,{'sub': 4', '5', '6', '7', '7, 'wherein Ris selected from NRR; a N-containing 5-membered heterocyclic non-aromatic ring optionally comprising one or more additional heteroatom(s) selected from N, O, or S, wherein said ring is optionally substituted once or more than once with Rand wherein said ring is attached to the rest of the molecule via a ring carbon atom; or a N-containing 6-membered heterocyclic non-aromatic monocyclic or bicyclic ring optionally comprising one or more additional heteroatom(s) selected from N, O, or S, wherein said ring is optionally substituted once or more than once with Rand wherein said ring is attached to the rest of the molecule via a ring carbon atom;'}{'sub': 5', '6, 'claim-text': [{'sub': '7', 'a 5-membered ring optionally comprising one additional heteroatom selected from N, O or S, optionally substituted once or more than once with R;'}, {'sub': '7', 'a 6-membered ring optionally comprising one additional heteroatom selected from N, O or S, optionally substituted once or more than once with R; or'}, {'sub': '7', 'a 7-membered spirocycle optionally comprising one additional heteroatom selected from N, O or S, optionally substituted once or more than once with R.'}], 'Rand Rtogether with the N atom to which they are attached form'}3. A compound of formula (I) in free form or in pharmaceutically acceptable salt form according to or claim 1 ,wherein{'sub': 2', '3, 'Rand Rare hydrogen;'}L is bond;{'sub': 4', '7, 'Ris a N-containing 6-membered heterocyclic non-aromatic bicyclic ring optionally comprising one or more additional heteroatom(s) selected ...

Verfahren zum mehrstufigen Vergleich zweier Textdokumente

Verfahren zum mehrstufigen Vergleich zweier Textdokumente durch einen Rechner, wobei das erste Dokument aus mehreren Einträgen mit jeweils einer Identifikationsnummer und das zweite Dokument aus mehreren hierarchisch gegliederten Kapiteln besteht, die folgenden Schritte umfassend: – Extraktion der in jedem Eintrag im ersten Dokument enthaltenen Parameter als Suchparameter, wobei die Suchparameter hierarchisch gegliedert sind – Abgleich der Suchparameter mit den Überschriften der Kapitel aus dem zweiten Dokument, wobei die höchste Hierarchieebene der Suchparameter der ersten Kapitelebene im zweiten Dokument und jede nächsttiefere Hierarchieebene der Suchparameter der nächsttieferen Unterkapitelebene im zweiten Dokument zugeordnet ist – Auswahl des gefundenen Unterkapitels aus dem zweiten Dokument, das der tiefsten Hierarchieebene der Suchparameter entspricht und ermitteln der Position im zweiten Dokument – Abspeichern der Position des gefundenen Unterkapitels aus dem zweiten Dokument mit ...

PROCEDURE FOR CALIBRATING A POSITION SENSOR IN A MOTOR VEHICLE TRANSMISSION

PROCEDURE AND DEVICE FOR THE PROOF OF MOLECULAR RECIPROCAL EFFECTS

WALLPAPER SUBSTRATE AND PROCEDURE FOR ITS PRODUCTION

Arylurea derivatives as modulators of chemokine receptor activity

Benzothiazolone compound

Abstract The present invention provides a compound of formula (1) in free form or in pharmaceutically acceptable salt form 5 (I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

DEVICE AND METHOD FOR DETECTING MOLECULAR INTERACTIONS

The invention relates to devices and methods for detecting specific interactions between probe and target molecules. The invention especially relates to a device for the qualitative and/or quantitative detection of molecular interactions between probe and target molecules, which comprises a) a microarray comprising a substrate on which probe molecules are immobilized on array elements, said microarray being located on a first surface of the device; and b) a reaction chamber that is defined between the first area with the microarray disposed thereon and a second surface, the distance between the microarray and the second surface being modifiable.

BENZOTHIAZOLONE COMPOUND

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

Vorrichtung zur Halterung eines Substanzbibliothekenträgers

Vorrichtung (1) zur Halterung eines Substanzbibliotheken trägers, wobei zwei miteinander fixierbare Halterelemente (101, 102) einen Schichtverbund bestehend au (i) einem Deckelelement (200), das auf seiner Unterseite eine Substanzbibliothek (201) in einer Detektionsfläche aufweist und das mindestens im Bereich der Detektionsfläche optisch durchlässig ist, (ii) einem dichtenden und eine umschlossene Aussparung (301) aufweisenden Zwischenelement (300) und (iii) einem mindestens im Bereich der Detektionsfläche des Deckelelements (200) optisch durchlässigen Bodenelement (400) bilden, wodurch eine optisch durchlässige Kammer (500) mit einem Kammerraum entsteht, wobei die Aussparung (301) des Zwischenelements (300) die geometrische Form des Kammerraums definiert und das Zwischenelement (300) elastisch mit Kanülen (2402, 2403) wiederholbar seitlich durchstechbar ist und beim Herausziehen der Kanülen (2402, 2403) der Kammerraum dicht verschlossen bleibt, so dass der Kammerraum durch seitliches ...

Tapetensubstrat und Verfahren zu seiner Herstellung

Der Erfindung, die ein Tapetensubstrat für eine trocken abziehbare Tapete mit minimaler Nassdehnung aus einer mehrschichtigen Bahn mit einer Unterseite und einer Oberseite, zwischen denen eine faserige untere Lage aus einem Faserstoffgemisch auf Zellulosebasis und Synthesefasern und eine faserige obere Lage aus einem synthesefaserfreien Faserstoffgemisch auf Zellulosebasis angeordnet ist, und ein Verfahren zur Herstellung eines solches Tapetensubstrates betrifft, liegt die Aufgabe zugrunde, ein nahezu fehlerfreies Bedrucken der Oberseite in guter Qualität insbesondere mittels Direktdruck zu ermöglichen und das es konstengünstig herstellbar ist. Dabei soll insbesondere eine Bedruckbarkeit dadurch erreicht werden, dass die Anzahl an Fehlstellen im Ausdruck minimiert wird. Gelöst wird dies dadurch, dass die untere Lage und die obere Lage durch Gautschen miteinander verfilzt sind und die Oberseite satiniert und für durch Direktdruck, insbesondere für Tiefdruck, direkt bedruckbar ausgebildet ...

PROCEDURE FOR THE PROOF OF NUCLEIC ACID MOLECULES AMPLIFIZIERTEN IN A POLYMERASE NUCLEAR CHAIN REACTION

Use of fused imidazole derivatives to mediate CCR3 related conditions

Pyrazoline derivatives and their use as selective androgen receptor modulators

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Indazole compounds for use in tendon and/or ligament injuries

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

ASSAYS USING BINDING MEMBERS AND REPORTED COMPOUNDS

PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

DEVICE AND PROCESS FOR ASSAYS USING BINDING MEMBERS

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network.

Aminopyridine derivatives and their use as selective alk-2 inhibitors

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

METHODS FOR DETECTING MULTIPLE NUCLEIC ACIDS IN A SAMPLE

The present invention relates to methods for determining the presence and/or amount of multiple nucleic acids in a sample.

FORMULATION COMPRISING BENZOTHIAZOLONE COMPOUND

The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5- hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

Muffenprüfgerät für Rohrstöße bei begehbaren Rohren

Cuff testing device for pipeline joints

The device has ring segments (2-5) corresponding to the inner diameter of the tested pipeline and an inflatable sealing ring (6) between the ring segments and the inside of the pipeline wall. The ring segments are connected with hinges (7) that can be fixed in position. The sealing ring has outer and inner inflatable chambers, with a filling connector between them.

Indazole compounds for use in tendon and/or ligament injuries

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Assays

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network.

Pyrazoline derivatives and their use as selective androgen receptor modulators

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Device and method for detecting molecular interactions

Abstract The invention relates to devices and methods for detecting specific interactions between probe and target molecules. The invention especially relates to a system for qualitative and/or quantitative detection of molecular interactions between probe molecules and target molecules in a sample solution, comprising: a mounting for a reaction cartridge comprising a reaction chamber formed between a first surface having a microarray arranged thereon and a second surface, wherein probe molecules are immobilized on array elements of the microarray and wherein the distance between the microarray and the second surface is variable; a detection unit which is configured in such a way that detection can be carried out in a reduced distance between the microarray and the second surface; and a means with which the microarray can be guided relative to the second surface.

METHODS AND DEVICES FOR DETERMINING VALUES INDICATIVE OF THE PRESENCE AND/OR AMOUNT OF NUCLEIC ACIDS

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative for the presence and/or amount of the target molecules, a microfluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the microfluidic network.

ASSAYS

... ²²A device comprising a rigid substrate, a flexible cover element at least ²partially covering the ²substrate, a first structure formed in the substrate, adapted for ²accommodating liquids and adapted for ²releasing contents of one or more cells, spores, or viruses, the contents ²including the target molecules, a ²second structure formed in the substrate, adapted for accommodating liquids ²and comprising at least one ²binding member adapted for capturing the target molecules and for determining ²a value indicative of the ²presence and/or amount of the target molecules, a micro fluidic network ²interconnecting at least the first ²structure and the second structure, and an actuator member adapted for ²effecting a fluid flow between the ²first structure and the second structure by pressing the flexible cover ²element against the substrate to ²selectively close a portion of the micro fluidic network.² ...

PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

Precision locking a database server during the upgrade of a system landscape

Various techniques are described for precisely locking database objects within a database during a system upgrade with the use of database freeze triggers. Some database freeze triggers can be utilized to lock transport requests while other database freeze triggers can be utilized to lock database objects such as exchange tables. For transport requests, techniques describe the use of a whitelist identify transport objects or transport object types which shall remain unblocked. As a result, a database freeze trigger can be generated for transport objects or transport object types that are not included in the whitelist. For database objects, techniques describe the identification of a tool or service which has been allowed during the upgrade. Database objects which can be modified during execution of the tool or service can be identified. Database freeze triggers can be generated for the database objects besides those identified.

AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

ASSAYS

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network.

PYRAZOLINE DERIVATIVES AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

ASSAYS

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative for the presence and/or amount of the target molecules, a microfluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the microfluidic network.

ASSAYS

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network. 1256-. (canceled)257. A method for detecting a human immunodeficiency virus (HIV) target nucleic acid in a liquid , comprising:a) introducing a liquid into a reaction chamber of a microfluidic device, the liquid comprising an HIV polynucleotide, binding the HIV polynucleotide to a first binding member located within the reaction chamber;b) amplifying the HIV polynucleotide within the reaction chamber to form amplicons, the amplification being performed in the presence of a reporter compound, binding a subset of the reporter compound to amplicons within the reaction chamber, binding a remaining subset of the reporter compound to a second binding member within the reaction chamber, and detecting the remaining subset of the reporter compound bound to the second binding member; andc) determining a value indicative of the presence and/or amount of reporter compound captured on the second binding member; and determining a value indicative of the amount of target nucleic acid based on the value indicative of the amount of reporter compound captured on the second binding member.258. The method of ...

Device and method for detecting molecular interactions

Assays

AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

Abstract The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form R1"'N 0R3 (1) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

Abstract The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form R1"'N 0R3 (1) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

ASSAYS USING BINDING MEMBERS AND REPORTER COMPOUNDS

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network.

Formulación que comprende un compuesto de benzotiazolona.

UNA COMPOSICION FARMACEUTICA ORAL SOLIDA QUE COMPRENDE DE 0,01 A 15% EN PESO DE (R)-7-(2-(1-(4-BUTOXI-FENIL)-2-METIL-PROPAN-2-IL-AMINO)-1-HIDROXI-ETIL)-5-HIDROXI-BENZO-[D]-TIAZOL-2(3H)-ONA Y EXCIPIENTES, EN DONDE EL COMPUESTO ESTA EN FORMA DE SAL DE ACETATO; SU METODO DE FABRICACION, UTIL PARA EL TRATAMIENTO O PREVENCION DE DISTROFIA MUSCULAR O CAQUEXIA, ENTRE OTRAS.

ZERO DOWNTIME UPGRADE OF SYSTEMS WITH DATABASE-SIDE REPLICATION

Implementations include providing, by a deploy tool, clone data components in the first database system, each clone data component being a copy of a data component, defining, by the deploy tool, a source-side green access schema in the first database system, the green access schema providing views to the clone data components, providing, by a replication system and based on statements received from the deploy tool, consumer-side clone data components in the first database system, each consumer-side clone data component being a copy of a respective data component, defining, by a replication system and based on statements received from the deploy tool, a consumer-side green access schema in the first database system, the green access schema providing views to the source-side clone data components, and, during execution of the upgrade, replicating, by a handler of the replication system, data from at least one source-side data component to a consumer-side component.

Indazole compounds for use in tendon and/or ligament injuries

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

METHODS AND DEVICES FOR DETERMINING VALUES INDICATIVE OF THE PRESENCE AND/OR AMOUNT OF NUCLEIC ACIDS

AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form 111-. (canceled)12. A method of inhibiting ALK-2 receptor activity in a subject , wherein the method comprises administering to the subject a therapeutically effective amount of a compound which is amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide , or a pharmaceutically acceptable salt thereof.13. A method of treating a disorder or disease selected from heterotopic ossification or fibrodysplasia ossificans progressiva , comprising administering to the subject a therapeutically effective amount of a compound which is amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)-nicotinamide , or a pharmaceutically acceptable salt thereof.1416-. (canceled)17. The method of claim 12 , wherein the compound is amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-((1R claim 12 ,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)-phenyl)nicotinamide claim 12 , or a pharmaceutically acceptable salt thereof.18. The method of claim 12 , wherein the compound is amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-((1S claim 12 ,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)-phenyl)nicotinamide claim 12 , or a pharmaceutically acceptable salt thereof.19. The method of claim 13 , wherein the compound is amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-((1R claim 13 ,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)-phenyl)nicotinamide claim 13 , or a pharmaceutically acceptable salt thereof.20. The method of claim 13 , wherein the compound is amino-N-(4-hydroxybicyclo-[2.2.2]octan-1-yl)-5-(4-((1S claim 13 ,5R)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)-phenyl)nicotinamide claim 13 , or a pharmaceutically acceptable salt thereof.21. The method of claim 13 , wherein the disorder or disease ...

Benzothiazolone compound

Abstract The present invention provides a compound of formula (1) in free form or in pharmaceutically acceptable salt form 5 (I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

Aminopyridine derivatives and their use as selective ALK-2 inhibitors

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Zero downtime for frequent software updates

In order to perform relatively frequent, zero-downtime software updates, a bridge schema corresponding to an original schema of a database system may be generated. Within the bridge schema, a plurality of views corresponding to a plurality of database tables of an application executing on an application server may be generated. A connection from the application to the original schema may be changed to the bridge schema, to thereby continue executing the application using the plurality of views. When a change file defining update changes to at least one original database table of the plurality of database tables is received, content of the at least one original database table may be synchronized with a target table reflecting the update changes. Then, the connection may be changed back to the original database schema to continue executing the software application, using the plurality of database tables and including the target table.

Vorrichtung zur Halterung und Detektion von Substanzbibliotheken

Die Erfindung betrifft Vorrichtungen zur Halterung und Detektion von Substanzbibliotheken.

Assays

BENZOTHIAZOLONE COMPOUND

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

Schrägkugellager

Schrägkugellager mit zwei Laufringen (10, 12), zwischen denen ein Kranz von Kugeln (14) so gehalten ist, dass die Angriffspunkte (p) der Laufringe auf jede Kugel (14) auf einer Hauptwirklinie (H) liegen, die schräg zur Achse (A) des Lages verläuft, dadurch gekennzeichnet, dass jeder Laufring (10, 12) einen axialen Fortsatz (16, 20) aufweist, der über die Scheitel der Kugeln (14) hinausragt und an dem ein jeweiliger Stützring (18, 22) so gehalten ist, dass die Angriffspunkte (q) der Stützringe auf jede Kugel (14) auf einer Linie liegen, die quer zur Hauptwirklinie (H) verläuft.

Aza-indazole compounds for use in tendon and/or ligament injuries

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Aza-indazole compounds for use in tendon and/or ligament injuries

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Pyridinone derivatives and their use as selective ALK-2 inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE FÓRMULA (I) EN FORMA LIBRE O EN FORMA DE SAL FARMACÉUTICAMENTE ACEPTABLE, UN MÉTODO PARA LA ELABORACIÓN DE LOS COMPUESTOS DE LA INVENCIÓN, Y SUS USOS TERAPÉUTICOS. LA PRESENTE INVENCIÓN ADEMÁS PROPORCIONA UNA COMBINACIÓN DE AGENTES FARMACOLÓGICAMENTE ACTIVOS Y UNA COMPOSICIÓN FARMACÉUTICA.

Formulation comprising benzothiazolone compound

The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5- hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

Benzothiazolone compound

Abstract The present invention provides a compound of formula (1) in free form or in pharmaceutically acceptable salt form 5 (I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

VORRICHTUNG ZUR HALTERUNG EINES SUBSTANZBIBLIOTHEKENTRÄGERS

Device and method for detecting molecular interactions

AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

Abstract The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form HH2N N R H R R1' N 0R3 5 (1) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Device and method for detecting molecular interactions

Method of calibrating a position sensor in an automotive transmission

A method of calibrating a position sensor in an automotive transmission having a transmission housing having mounted therein a casing (10) for the position sensor which includes a pressure member (14) movably supported in the casing (10), and an electrical displacement sensor (38) actuated by the pressure member (14) for measuring the position of the pressure member (14) relative to the casing (10), such that, after the casing (10) of the position sensor has been mounted in the transmission housing, the displacement sensor (38) is used for performing at least one calibration measurement for at least one gear position, and, for each gear position to be detected, a tolerance range for the corresponding measurement value of the displacement sensor is defined on the basis of the result of the calibration measurement.

Organic compounds

The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R1, R2, Ar, A and B are defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions

The use of compound of formula I in the preparation of a medicament, e.g. for the treatment of condition mediated by CCR3.

Rast- und Sensoreinrichtung für ein Schaltgetriebe

Rast- und Sensoreinrichtung für ein Schaltgetriebe, mit einem auf einer Schaltwelle (12) angeordneten Schaltgebirge (14), einem verschiebbar in einem Gehäuse (10) gelagerten Rastelement (16), das elastisch gegen das Schaltgebirge (14) vorgespannt ist, und einem Sensor (24) zur Messung des Weges (s), den das Rastelement (16) relativ zum Gehäuse (10) zurücklegt, während es das Schaltgebirge (14) abfährt, dadurch gekennzeichnet, dass die Kontur des Schaltgebirges (14) für mindestens eine Schaltposition eine Unstetigkeitsstelle (38) aufweist, die von dem Rastelement (16) überfahren wird, wenn dieses sich aus einer Neutralgasse (26) auf ein der betreffenden Schaltposition zugeordnetes Plateau (28, 30, 32, 34, 40, 42) bewegt.

METHODS FOR DETECTING MULTIPLE NUCLEIC ACIDS IN A SAMPLE USING REPORTER COMPOUNDS AND BINDING MEMBERS THEREOF

The present invention relates to methods for determining the presence and/or amount of multiple nucleic acids in a sample.

INDAZOLE COMPOUNDS FOR USE IN LESIONS OF TENDONS/LIGAMENTS VIA OTA

Además se proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica utilizada en el tratamiento de las lesiones de tendón. Reivindicación 1: Un compuesto de la fórmula (1) en forma libre ó en forma de sal farmacéuticamente aceptable, caracterizada porque, R¹ se selecciona a partir de alquilo C₁₋₃, halógeno y alcoxilo C₁₋₃; R² se selecciona independientemente entre alquilo C₁₋₃ y halógeno; n es 1 ó 2, R³ se selecciona a partir de H y alquilo C₁₋₃, y R⁴ se selecciona a partir de un cicloalquilo C₄₋₆ sustituido opcionalmente una vez o más de una vez por R⁵; un anillo no aromático heterocíclico de 5 ó 6 miembros que comprende al menos un heteroátomo seleccionado entre N, O ó S, sustituido opcionalmente una vez o más de una vez independientemente por hidroxilo, alquilo C₁₋₃, alcoxilo C₁₋₃; en donde R⁴ no es 4-hidroxiciclohexilo o tetrahidrofurano; o R³ y R⁴ junto con el átomo N al cual están unidos, forman un anillo no aromático heterocíclico de 4, 5 ó ...

Verfahren zum Nachweis von in einer Polymerase-Kettenreaktion amplifizierten Nukleinsäuremolekülen

The invention relates to a device and method for qualitatively and/or quantitatively identifying nucleic acid molecules that are amplified in a polymerase chain reaction.

Vorrichtung und Verfahren zum Nachweis von molekularen Wechselwirkungen

Die Erfindung betrifft Vorrichtungen und Verfahren zum Nachweis von spezifischen Wechselwirkungen zwischen Sonden- und Targetmolekülen. DOLLAR A Insbesondere betrifft die Erfindung eine Vorrichtung zum qualitativen und/oder quantitativen Nachweis von molekularen Wechselwirkungen zwischen Sonden- und Targetmolekülen, umfassend: DOLLAR A a) einen Mikroarray mit einem Substrat, auf dem auf Array-Elementen Sondenmoleküle immobilisiert sind, wobei der Mikroarray auf einer ersten Fläche der Vorrichtung angeordnet ist, und DOLLAR A b) eine Reaktionskammer, die zwischen der ersten Fläche mit dem darauf angeordneten Mikroarray und einer zweiten Fläche gebildet ist, DOLLAR A wobei der Abstand zwischen dem Mikroarray und der zweiten Fläche veränderbar ist.

BENZOTHIAZOLONE COMPOUND

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form 2. The method according to claim 1 , in which the compound of formula (I) is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in free form.3. The method according to claim 1 , in which the compound of formula (I) is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in acetate salt form.5. The method according to claim 4 , wherein the hypertrophy is selective for skeletal muscle over cardiac muscle.6. The method according to claim 4 , in which the compound of formula (I) is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in free form.7. The method according to claim 4 , in which the compound of formula (I) is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in acetate salt form.8. The method according to claim 5 , in which the compound of formula (I) is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in free form.9. The method according to claim 5 , in which the compound of formula (I) is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in acetate salt form. The present invention relates to a benzothiazolone compound, to its preparation, to its medical use as a beta-2 adrenoceptor agonist and to medicaments, pharmaceutical compositions and combinations comprising it.Benzothiazolone compounds which are beta-2-adrenoceptor agonists are described in WO2004/16601 and WO2006/056471. WO2005/110990 also describes benzo-condensed heterocycles as beta-2 agonists.While beta-2 agonists have long been known for their bronchodilating properties, they are also known for their capability to produce skeletal muscle hypertrophy. ...

Device and method for the detection of particles

The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or second surface. The invention also relates to corresponding methods for the detection of particles.

FORMULATION COMPRISING BENZOTHIAZOLONE COMPOUND

The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5- hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

Aminopyridine derivatives and their use as selective alk-2 inhibitors

Method and device for the detection of molecular interactions

The invention relates to devices and methods for the detection of specific interactions between probe and target molecules. In particular, the invention relates to methods for the qualitative and/or quantitative detection of targets, including: introducing a sample containing targets into a reaction chamber formed between a first surface of the device and a second surface of a device, which is preferably located opposite to the first surface, wherein the distance between the first and the second surface is variable; and detecting the targets.

Getriebesensor

Getriebesensor zur Erfassung mindestens zweier Schaltstellungen eines Kraftfahrzeuggetriebes, mit einem Taster (10), der dazu ausgebildet ist, ein Schaltgebirge auf einer Schaltwelle des Getriebes abzutasten und eine Axialbewegung eines Stößels (26) zu steuern, und mit einer durch den Stößel (26) betätigten elektromechanischen Sensoreinrichtung (12) zur Erfassung mindestens dreier Axialpositionen des Stößels, wobei mindestens zwei dieser Axialpositionen jeweils einer der zu erfassenden Schaltstellungen zugeordnet sind, dadurch gekennzeichnet, dass die Sensoreinrichtung (12) eine mit dem Stößel bewegliche Kontaktbrücke (48) zum Schließen eines elektrischen Kontakts in einer ersten axialen Position des Stößels (26) sowie einen mit dem Stößel beweglichen Magneten (42) zur berührungslosen Betätigung eines Magnetschalters (44) in einer zweiten Position des Stößels aufweist.

Arylurea derivatives as modulators of chemokine receptor activity

A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.

Vorrichtung und Verfahren zum Nachweis von molekularen Wechselwirkungen

Die Erfindung betrifft Vorrichtungen und Verfahren zum Nachweis von spezifischen Wechselwirkungen zwischen Sonden- und Targetmolekülen. DOLLAR A Insbesondere betrifft die Erfindung Verfahren zum qualitativen und/oder quantitativen Nachweis von Targets, umfassend die folgenden Schritte: DOLLAR A a) Einbringen einer Probe, enthaltend Targets, in eine Reaktionskammer, die zwischen einer ersten Fläche der Vorrichtung und einer zweiten Fläche einer Vorrichtung, die bevorzugt der ersten Fläche gegenüberliegt, gebildet ist, wobei der Abstand zwischen der ersten und der zweiten Fläche veränderbar ist; DOLLAR A b) Detektieren der Targets. DOLLAR A Die Erfindung betrifft auch eine Vorrichtung zum qualitativen und/oder quantitativen Nachweis von molekularen Wechselwirkungen zwischen Sonden- und Targetmolekülen, umfassend eine Reaktionskammer, die zwischen einer ersten Fläche der Vorrichtung und einer zweiten Fläche der Vorrichtung, die der ersten Fläche gegenüberliegt, gebildet ist, wobei der Abstand ...

Method for calibrating a position sensor in a motor vehicle gear

The present invention provides a method for calibrating a position sensor in a motor vehicle transmission comprising a gear housing with a housing (10) included therein for the position sensor, said sensor housing comprising a pressure member (14) that is held moveably inside the housing (10), said member being pre-stressed elastically against a switch bump and comprising an electric path sensor (38) actuated by the pressure member (14) for measuring the position of the pressure member (14) relative to the housing (10), characterized in that after the housing (10) of the position sensor is installed into the gear housing, at least one calibration measurement is carried out by the path sensor (38) for at least one gear position and for the associated measured value of the path sensor a tolerance zone is defined for each gear position to be detected using the results of the respective calibration measurement.

Device for supporting carrier of a substance library, useful in e.g. microarray based assays, comprises two connected elements that define a transparent analysis chamber

Device (1) for supporting a substance library carrier in which two mutually connectable elements (101; 102) form a layered composite so as to create an optically transparent chamber (500). Device (1) for supporting a substance library carrier in which two mutually connectable elements (101; 102) form a layered composite so as to create an optically transparent chamber (500). The composite comprises: (i) a cover (200) that has on its under side a detection surface with the substance library (201) and is optically transparent, at least in the region of the detection surface; (ii) an intermediate element (300) having a sealable opening; and (iii) an optically transparent base element (400), at least in the region of the detection surface. An Independent claim is also included for a device (2000) for filling (1).

Vorrichtung zur Vervielfältigung und zum Nachweis von Nukleinsäuren

Die Erfindung betrifft eine Vorrichtung zur Vervielfältigung und zum Nachweis von Nukleinsäuren, umfassend eine Temperatursteuerungs- und/oder -regeleinheit; eine Reaktionskammer, die einen Träger mit einer Detektionsfläche enthält, auf der eine Substanzbibliothek immobilisiert ist, wobei die Temperatur in der Reaktionskammer durch die Temperatursteuerungs- und -regeleinheit steuerbar und/oder regelbar ist; und ein optisches System, mit dem der zeitliche Verlauf von Niederschlagsbildung auf der Detektionsfläche detektierbar ist. The invention relates to a device for the duplication and detection of nucleic acids, comprising a temperature control and / or regulating unit; a reaction chamber which contains a carrier with a detection surface on which a substance library is immobilized, the temperature in the reaction chamber being controllable and / or regulatable by the temperature control and regulating unit; and an optical system with which the time course of precipitation formation on the detection surface can be detected.

Pyridinone derivatives and their use as selective ALK-2 inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases. © KIPO & WIPO 2008 ...

Latching and sensor device for synchronous gear box for motor cars, has switching ground with contour comprising discontinuity point, which is transferred from latch element when latch element is moved from neutral lane to plateaus

The device has a switching ground (14) arranged on a shift shaft (12), and a latch element (16), which is displaceably supported in a housing (10) and is pre-tensioned against the switching ground. A sensor (24) measures a path, which reclines the latch element relative to the housing, and drives off the ground. A contour of the ground comprises a discontinuity point (38) for a shift position, where the discontinuity point is transferred from the latch element when the latch element is moved from a neutral lane (26) to plateaus (28-34), which are assigned to the shift position. An independent claim is also included for a synchronous gear box for motor cars, comprising a racing and a sensor device and an electronic device.

Pyrazoline derivatives and their use as selective androgen receptor modulators

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

VERFAHREN ZUM NACHWEIS VON IN EINER POLYMERASE-KETTENREAKTION AMPLIFIZIERTEN NUKLEINSÄUREMOLEKÜLEN

Drehlager mit Axial-Rillenkugellager

Drehlager, insbesondere für Fahrzeugsitze, mit zwei Lagerscheiben (14), die um eine Drehachse relativ zueinander drehbar sind und aneinander durch ein Axial-Rillenkugellager (16) abgestützt sind, das zwei Lagerringe (20, 22) aufweist, die jeweils zwei ringförmige Rillen (26, 32) zur Aufnahme von Lagerkugeln (34) bilden, dadurch gekennzeichnet, dass die Lagerringe (20, 22) zwei C-Profile bilden, deren parallele Schenkel (24, 30) rechtwinklig zur Drehachse orientiert sind und die so ineinander greifen, dass das eine C-Profil das andere umgreift, und dass die Rillen (26, 32) in den paarweise parallel zueinander verlaufenden Schenkeln (24, 30) dieser C-Profile gebildet sind.

Device and Method for the Detection of Particles

The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or second surface. The invention also relates to corresponding methods for the detection of particles. 187.-. (canceled)88. A method for the qualitative and/or quantitative detection of particles , comprising:a) positioning a sample comprising one or more species of particles to be detected in a reaction chamber comprising a capillary gap defining a volume;b) positioning of at least a subset of the one or more species of particles to be detected in the capillary gap by one or more displacers;c) detecting multiple particles in the capillary gap, and thereby determining a value indicative of the number of particles belonging to at least one of species of particles.89. The method of claim 88 , wherein the reaction chamber comprises a first surface and a second surface opposite to the first surface and comprising an area made of an elastically deformable material claim 88 , and wherein the positioning of at least a subset of the one or more species of particles comprises varying the distance between the first surface and the second surface in the area made of an elastically deformable material.90. The method of claim 89 , wherein varying the distance includes applying a pressure to the elastically deformable material by the one or more displacers.91. The method of claim 89 , wherein at least a part of the sample is displaced from the capillary gap by varying the pressure applied to the ...

Benzothiazolone compound

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

Rolling Bearing for a Shaft

A roller bearing for a shaft that has a cylindrical peripheral surface, the bearing including a race () to be fitted onto the shaft, and roller bodies () arranged to roll on the race (), the race () having a polygonal internal cross-section, so that it engages the peripheral surface of the shaft only in the vicinity of the center of each side () of the polygon.

Device and Method for the Detection of Particles

The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or second surface. The invention also relates to corresponding methods for the detection of particles. 181.-. (canceled)82. A device , comprising:a detection chamber configured to receive a sample comprising multiple particles,an actuator configured to displace some of the multiple particles from the detection chamber so that only a proper subset of the multiple particles remains,a detector configured to detect particles of the subset of particles, anda processor configured to determine, based on the detected particles, a value indicative of the number of particles of the proper subset of particles.83. The device of claim 82 , wherein the device is configured to operate the actuator to (a) reintroduce at least some of the displaced multiple particles to the detection chamber and claim 82 , subsequently claim 82 , (b) displace some of the multiple particles from the detection chamber so that only a second proper subset of the multiple particles remains and the processor is configured to operate the detector to detect particles of the second proper subset and determine claim 82 , based on the detected particles claim 82 , a value indicative of the number of particles of the second proper subset of particles.84. The device of claim 83 , further comprising a reservoir capable of receiving particles displaced from the detection chamber and from which particles can be reintroduced to the ...

Formulation comprising benzothiazolone compound

The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt.

Electrical Powered Weight and Fullness Level System

A collection apparatus weight and fullness level reporting system includes: an inlet; a removable collection bin receiving material placed into the collection apparatus; a compacting mechanism including a ram body, wherein the ram body travels between a home position located above the collection bin to a maximum travel position located inside the collection bin, wherein during each compaction cycle the ram body travels along a variable length of the compaction path; a fullness-reporting module that determines the height of the material in the collection bin; and a controller that determines the length of the compaction path the ram body travels during each compaction cycle based on the input received from the fullness reporting module, wherein at the end of each compaction cycle in which the material height is below a maximum height, the ram body is brought to rest at a height below the home position. 1. A collection apparatus weight and fullness level reporting system comprising:an inlet providing passage to the interior of the collection apparatus;a removable collection bin receiving material placed into the collection apparatus through the inlet;a compacting mechanism including a ram body, wherein the ram body travels along a compaction path between a home position located above the collection bin to a maximum travel position located inside the collection bin, wherein during each compaction cycle the ram body travels along a variable length of the compaction path;a fullness-reporting module including a height sensor that determines the height of the material in the collection bin; anda controller receiving input from the fullness reporting module and controlling the travel of the ram body, wherein the controller determines the length of the compaction path the ram body travels during each compaction cycle based on the input received from the fullness reporting module, wherein at the end of each compaction cycle in which the material height is below a maximum ...

Benzothiazolone compound

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

Precision Locking a Database Server During the Upgrade of a System Landscape

Various techniques are described for precisely locking database objects within a database during a system upgrade with the use of database freeze triggers. Some database freeze triggers can be utilized to lock transport requests while other database freeze triggers can be utilized to lock database objects such as exchange tables. For transport requests, techniques describe the use of a whitelist identify transport objects or transport object types which shall remain unblocked. As a result, a database freeze trigger can be generated for transport objects or transport object types that are not included in the whitelist. For database objects, techniques describe the identification of a tool or service which has been allowed during the upgrade. Database objects which can be modified during execution of the tool or service can be identified. Database freeze triggers can be generated for the database objects besides those identified. 1. A computer-implemented method comprising:initiating, by a processor, an upgrade of a system within a system landscape;generating, by the processor, a plurality of database freeze triggers configured to prevent modification of a plurality of data objects within a database of the system while the upgrade is being performed;first determining, by the processor, a tool or application of the system that has been enabled to operate while the upgrade is being performed;identifying, by the processor, a database object from the plurality of database objects that is modifiable by the enabled tool or application; anddeleting, by the processor, a database freeze trigger corresponding to the database object to allow changes to be made to the database object while the upgrade is being performed.2. The computer-implemented method of claim 1 , further comprising:receiving, by the processor, a transport request to transport content from the system to another system, the content having a transport object type; andsecond determining, by the processor, whether ...

METHODS FOR DETECTING MULTIPLE NUCLEIC ACIDS IN A SAMPLE

The present invention relates to methods for determining the presence and/or amount of multiple nucleic acids in a sample. 1. A method of determining the presence and/or amount of nucleic acids in a sample , comprising(a) providingan amount of a first nucleic acid;an amount of a second nucleic acid;an amount of a FRET compound capable of forming complexes with the first nucleic acid, wherein the FRET compound comprises a binding portion specific to a region of the first nucleic acid, and a first detectable label that has, in an uncomplexed state, a first detectable characteristic and, in a complexed state, a second detectable characteristic;an amount of a reporter compound capable of forming complexes with the second nucleic acid, wherein each reporter compound comprises a binding portion specific to a region of the second nucleic acid and a second detectable label; anda binding member capable of capturing the reporter compound;wherein forming of complexes of the second nucleic acid with the reporter compound inhibits capturing of the reporter compound by the binding member;(b) subjecting the first and/or second nucleic acid to amplification;(c) forming complexes each comprising a first nucleic acid and a FRET compound;(d) forming complexes of a subset of the amount of reporter compound with a second nucleic acid;(e) capturing a remaining subset of the amount of reporter compound not in complex with a second nucleic acid on the binding member;(f) determining a value indicative for the presence and/or amount of first nucleic acid captured by FRET compounds; and(g) determining a value indicative for the presence and/or amount of reporter compound captured on the binding member.2. The method of claim 1 , further comprising determining a value indicative for the presence and/or amount of second nucleic acid based on the value indicative for the presence and/or amount of reporter compound captured on the binding member.3. The method of claim 1 , wherein the first ...

Indazole Compounds for Use in Tendon and/or Ligament Injuries

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form 3. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , wherein{'sub': '1', 'Ris selected from methyl, chloro, fluoro and methoxy; and'}{'sub': '2', 'Ris selected from methyl and chloro.'}4. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , wherein{'sub': '3', 'Ris H; and'}{'sub': 4', '4', '6', '5, 'Ris a C-Ccycloalkyl substituted once or twice with R.'}5. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , wherein Ris independently selected from hydroxyl claim 1 , haloC-Calkyl claim 1 , halogen claim 1 , and C-Calkyl.6. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , wherein Rand Rtogether with the N atom to which they are attached form a 4- claim 1 , 5- or 6-membered heterocyclic ring substituted once claim 1 , twice or three times with R.7. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , wherein Ris independently selected from halogen claim 1 , hydroxyC-Calkyl claim 1 , hydroxyl claim 1 , and C-Calkyl.8. A compound according to in free form or in pharmaceutically acceptable salt form which is selected from5-(2-chloro-4-((3,3-dimethylazetidin-1-yl)sulfonyl)phenyl)-4-methyl-1H-indazol-3-amine;1-((4-(3-amino-4-methyl-1H-indazol-5-yl)-3-chlorophenyl)sulfonyl)pyrrolidin-3-ol;1-((4-(3-amino-4-methyl-1H-indazol-5-yl)-3-fluorophenyl)sulfonyl)pyrrolidin-3-ol;1-((4-(3-amino-4-methyl-1H-indazol-5-yl)-3-methylphenyl)sulfonyl)pyrrolidin-3-ol;1-((4-(3-amino-4-chloro-1H-indazol-5-yl)-3-fluorophenyl)sulfonyl)pyrrolidin-3-ol;1-((4-(3-amino-4-chloro-1H-indazol-5-yl)-3-methylphenyl)sulfonyl)pyrrolidin-3-ol;1-((4-(3-amino-4-chloro-1H-indazol-5-yl)-3-chlorophenyl)sulfonyl)pyrrolidin-3-ol;4-(3-amino-4-methyl-1H-indazol-5-yl)-N-(3-hydroxycyclobutyl)-3- ...

Device and Method for the Detection of Particles

The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or second surface. The invention also relates to corresponding methods for the detection of particles. 287-. (canceled) This application claims the benefit of German patent application DE 10 2005 052 752, which is incorporated herein by reference in its entirety. The present application further relates to German patent application DE 10 2005 052 713 and to the International Patent Application entitled “Method and device for the detection of molecular interactions”, filed on Nov. 6, 2006 (Maiwald reference number: C 7794), both of which applications are incorporated herein by reference in their entireties.The invention relates to devices and methods for the detection of particles.The detection of the presence and/or the enumeration of absolute levels of one or more species of particles like cells or viruses in samples such as human and non-human body fluids is of primary importance in determining the state of health of human beings and mammals in general. Clinically important examples of such applications involve counting of CD4+ cells in HIV-positive subjects, of granulocytes and platelets in patients treated with chemotherapy, and of leukocytes in blood bags. Non-medical applications, on the other hand, include the detection of (bacterial) contaminants in environmental samples such as sewage or in food products.The main analytical platform for performing such analyses is currently flow ...

BENZOTHIAZOLONE COMPOUND

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form 2. A compound according to which is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in free form.3. A compound according to which is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in acetate salt form.4. A compound according to which is (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in glycolate salt form.5. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to and one or more pharmaceutically acceptable carriers.6. A pharmaceutical composition according to wherein one of the pharmaceutically acceptable carriers is benzyl alcohol.7. A combination comprising a therapeutically effective amount of a compound according to and one or more therapeutically active co-agents.11. A process according to wherein the LG is chloro. The present invention relates to a benzothiazolone compound, to its preparation, to its medical use as a beta-2 adrenoceptor agonist and to medicaments, pharmaceutical compositions and combinations comprising it.Benzothiazolone compounds which are beta-2-adrenoceptor agonists are described in WO2004/16601 and WO2006/056471. WO2005/110990 also describes benzo-condensed heterocycles as beta-2 agonists.While beta-2 agonists have long been known for their bronchodilating properties, they are also known for their capability to produce skeletal muscle hypertrophy.Numerous studies have focused on therapeutic applications of the anabolic properties of beta-2 agonists for ameliorating muscle wasting and improving muscle function. However, this class of compounds has also been associated with undesirable side-effects, including increased risk of adverse cardiovascular-related events. Thus, the use of beta-2 agonists in muscle ...

ENABLING CORRECTIONS DURING UPGRADE PROCEDURE

Methods, systems, and computer-readable storage media for applying corrections during an upgrade procedure of a software management system include actions of receiving a set of white-listed object types, receiving a set of corrections to be imported, the set of corrections including a set of objects, to which corrections are to be applied during the upgrade procedure, determining a set of object types included in the set of corrections, the set of object types including one or more object types, and selectively permitting one or more transport requests to effect corrections of the set of corrections to be issued during the upgrade procedure based on the set of object types and the set of white-listed object types. 1. A computer-implemented method for applying corrections during an upgrade procedure of a software management system , the method being executed using one or more processors and comprising:receiving, by the one or more processors, a set of white-listed object types;receiving, by the one or more processors, a set of corrections to be imported, the set of corrections comprising a set of objects, to which corrections are to be applied during the upgrade procedure;determining, by the one or more processors, a set of object types included in the set of corrections, the set of object types comprising one or more object types; andselectively permitting, by the one or more processors, one or more transport requests to effect corrections of the set of corrections to be issued during the upgrade procedure based on the set of object types and the set of white-listed object types.2. The method of claim 1 , wherein selectively permitting one or more transport requests comprises determining that a correction in a set of corrections includes an object having an object type that is included in the set of white-listed object types claim 1 , and in response claim 1 , permitting a transport request to effect the correction.3. The method of claim 1 , wherein selectively ...

AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form 19-. (canceled)10. A compound which is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R ,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide fumarate or a hydrate thereof.11. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to and one or more pharmaceutically acceptable carriers.12. A method of inhibiting ALK-2 receptor activity in a subject claim 10 , wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to .13. A method of treating a disorder or disease selected from heterotopic ossification or fibrodysplasia ossificans progressiva claim 10 , comprising administering to the subject a therapeutically effective amount of the compound according to .1416.-. (canceled)17. The compound according to claim 10 , wherein the compound is 2-amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R claim 10 ,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide fumarate dihydrate.18. The compound of claim 17 , which is crystalline.19. The compound of having a DSC thermogram which is characterized by an endothermic peak at about 160° C.20. The compound of characterized by an X-ray powder diffraction pattern having peaks expressed in degrees-2-theta at angles (±0.2 degrees) of 7.0 claim 17 , 14.2 claim 17 , 15.6 claim 17 , 16.2 claim 17 , 18.0 claim 17 , 19.2 claim 17 , and 25.5.21. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to and one or more pharmaceutically acceptable carriers.22. A method of inhibiting ALK-2 receptor activity in a subject claim 17 , wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to .23. A method of treating heterotopic ossification or fibrodysplasia ...

METHOD AND DEVICE FOR THE DETECTION OF MOLECULAR INTERACTIONS

The present invention relates to devices and methods for the detection of analytes. In particular, the invention relates to methods for the qualitative and/or quantitative detection of analytes, comprising a microarray on a substrate, onto which probe molecules are immobilized on array elements, said microarray being disposed on a first surface of the device; and a detection chamber formed between the first surface including the microarray disposed thereon and a second surface, wherein the distance between the microarray and the second surface is variable, and wherein the second surface has a displacement structure. 1. Device for the qualitative and/or quantitative detection of analytes , comprising:a) a micro array on a substrate, onto which probe molecules are immobilized on array elements, said micro array being disposed on a first surface of the device; andb) a detection chamber formed between the first surface including the micro array disposed thereon and a second surface, wherein the distance between the micro array and the second surface is variable, and wherein the second surface has a displacement structure.268. -. (canceled) This application claims the benefit of German patent application DE 10 2005 052 713, which is incorporated herein by reference in its entirety. The present application further relates to German patent application DE 10 2005 052 752 and to the International Patent Application entitled “Device and method for the detection of particles”, filed on Nov. 6, 2006 (Maiwald reference number C 7759), both of which applications arc incorporated herein by reference in their entireties.The invention relates to devices and methods for the determination of analytes (e.g., target molecules) by, for example, the determination of interactions (e.g., specific interactions) between probe molecules and the target molecules.Biomedical tests are often based on the detection of an interaction between a molecule, which is present in known amount and position ...

Benzothiazolone compound

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

METHOD AND DEVICE FOR THE DETECTION OF MOLECULAR INTERACTIONS

The invention relates to devices and methods for the detection of specific interactions between probe and target molecules. In particular, the invention relates to methods for the qualitative and/or quantitative detection of targets, including: introducing a sample containing targets into a reaction chamber formed between a first surface of the device and a second surface of a device, which is preferably located opposite to the first surface, wherein the distance between the first and the second surface is variable; and detecting the targets. 162-. (canceled)63. A device for qualitatively and/or quantitatively detecting molecular interactions between probe molecules and target molecules in a sample solution , said device comprising:a micro-array having a substrate, on which probe molecules are immobilized on array elements, said micro-array being arranged on a first surface of the device; anda reaction chamber formed between the first surface having said micro-array arranged thereon, and a second surface, wherein the distance between said micro-array and said second surface is variable such that the sample solution between said micro-array and said second surface can be essentially removed without removing the sample solution from the reaction chamber.64. The device according to claim 63 , wherein the device further comprises a means for varying the distance between said micro-array and said second surface in such a way that the sample solution between said micro-array and said second surface can be essentially removed.65. The device according to claim 64 , wherein the distance between said micro-array and the second surface is variable in a range of about 0 to about 1 mm.66. The device according to claim 63 , wherein the device further comprises a temperature control unit and/or temperature regulating unit for controlling and/or regulating the temperature within the reaction chamber.67. The device according to claim 63 , wherein the device comprises a detection ...

AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form 117.-. (canceled)19. The method of claim 18 , wherein:{'sub': '1', 'Ris chloro or methyl; and'}{'sub': 2', '2', '5', '6, 'Ris SONRR.'}20. The method of claim 18 , wherein:{'sub': '8', 'Ris H or methyl;'}{'sub': 6', '4', '6', '7, 'Ris C-Ccycloalkyl optionally substituted once or more than once with R; and'}{'sub': 7', '1', '3', '1', '3', '1', '3, 'Ris independently selected from hydroxyl, haloC-Calkyl, halogen, C-Calkyl, and hydroxyC-Calkyl.'}21. The method of claim 18 , wherein the compound is 4-(3-amino-1H-pyrazolo[4 claim 18 ,3-b]pyridin-5-yl)-3-chloro-N-((1s claim 18 ,3s)-3-hydroxy-3-(trifluoromethyl)cyclobutyl)benzenesulfonamide or a pharmaceutically acceptable salt thereof.22. The method of claim 18 , wherein the compound is 4-(3-amino-1H-pyrazolo[4 claim 18 ,3-b]pyridin-5-yl)-N-(3 claim 18 ,3-difluorocyclobutyl)-3-methylbenzenesulfonamide or a pharmaceutically acceptable salt thereof.23. The method of claim 18 , wherein the compound is 4-(3-amino-1H-pyrazolo[4 claim 18 ,3-b]pyridin-5-yl)-N-((1s claim 18 ,3s)-3-hydroxy-3-(trifluoromethyl)cyclobutyl)-N claim 18 ,3-dimethylbenzenesulfonamide or a pharmaceutically acceptable salt thereof.24. The method of claim 18 , wherein the compound is 4-(3-amino-1H-pyrazolo[4 claim 18 ,3-b]pyridin-5-yl)-3-chloro-N-(1 claim 18 ,1-dioxidothietan-3-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof.25. The method of claim 18 , wherein the compound is 4-(3-amino-1H-pyrazolo[4 claim 18 ,3-b]pyridin-5-yl)-3-chloro-N-phenylbenzenesulfonamide or a pharmaceutically acceptable salt thereof.26. The method of claim 18 , wherein the compound is 1-((4-(3-amino-1H-pyrazolo[4 claim 18 ,3-b]pyridin-5-yl)-3-methylphenyl)sulfonyl)-3-(trifluoromethyl)azetidin-3-ol or a pharmaceutically acceptable salt thereof.27. The method of claim 18 , wherein the tendon injury is selected from a tendon partial rupture claim 18 , a ...

ASSAYS

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network. 1. A method , comprising: an amount of a reporter compound,', 'a binding member capable of capturing the reporter compound, and', 'an amount of a target nucleic acid capable of forming complexes with the reporter compound, the forming of complexes with the reporter compound inhibiting capturing of the reporter compound by the binding member;, 'forming a composition of matter comprisingforming complexes of a subset of the amount of reporter compound with at least a subset of the amount of target nucleic acid;capturing a remaining subset of the amount of reporter compound not in complex with a target nucleic acid on the binding member; anddetermining a value indicative of the presence and/or amount of reporter compound captured on the binding member.2. The method of claim 1 , further comprising determining a value indicative of the presence and/or amount of target nucleic acid based on the value indicative of the presence and/or amount of reporter compound captured on the binding member.3. The method of claim 1 , further comprising releasing the remaining subset of the amount of reporter ...

METHOD AND DEVICE FOR THE DETECTION OF MOLECULAR INTERACTIONS

The invention relates to devices and methods for the detection of specific interactions between probe and target molecules. In particular, the invention relates to methods for the qualitative and/or quantitative detection of targets, including: introducing a sample containing targets into a reaction chamber formed between a first surface of the device and a second surface of a device, which is preferably located opposite to the first surface, wherein the distance between the first and the second surface is variable; and detecting the targets. 120-. (canceled)21. A device , comprising:a detection zone defined at least in part between a first surface and a second surface, the detection zone being configured to accommodate a mixture including (a) a liquid, (b) a first complex including a first analyte and a first portion of a first optical label, and (c) a second portion of the first optical label, the second portion being in an uncomplexed state with respect to the first analyte, wherein the second portion has a greater mobility than the first complex;an actuator configured to vary a distance between the first surface and the second surface and thereby displace at least a portion of the mixture from between the first surface and the second surface without introducing a liquid free of the first optical label between the first surface and the second surface; anda detector configured to detect the optical label in the detection zone.22. The device of claim 21 , wherein the first analyte is immobilized on the first surface.23. The device of claim 22 , wherein the first analyte includes a nucleic acid claim 22 , apeptide, a protein, an antigen, an antibody, a carbohydrate, a low molecular weight chemical compound, or a cell.24. The device of claim 23 , wherein the first analyte includes a nucleic acid.25. The device of claim 24 , further comprising a microarray immobilized on the first surface.2631-. (canceled)32. The device of claim 21 , wherein the actuator is configured ...

PYRAZOLINE DERIVATIVES AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 6. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 ,wherein{'sub': 1', '2', '3, 'Ris methyl; Ris chloro; Ris cyano.'}7. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , wherein Ris selected from hydroxy claim 1 , C-Calkoxy.8. A compound according to in free from or in pharmaceutically acceptable salt form claim 1 , wherein Rif present is selected from halogen claim 1 , hydroxy.9. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , wherein Rif present is selected from halogen claim 1 , hydroxy.10. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , wherein Rif present is hydrogen.11. A compound according to in free form or in pharmaceutically acceptable salt form claim 1 , which is selected from2-chloro-4-(4-hydroxy-3-methoxy-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazol-2-yl)-3-methylbenzonitrile;2-chloro-4-(3,4-dihydroxy-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazol-2-yl)-3-methylbenzonitrile;2-chloro-4-(3-ethoxy-4-hydroxy-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazol-2-yl)-3-methylbenzonitrile;2-chloro-4-(4-hydroxy-3-isopropoxy-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazol-2-yl)-3-methylbenzonitrile;2-chloro-4-(5-hydroxy-3-methoxy-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazol-2-yl)-3-methylbenzonitrile;2-chloro-4-(3-methoxy-5-oxo-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazol-2-yl)-3-methylbenzonitrile;2-chloro-4-(3,5-dihydroxy-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazol-2-yl)-3-methylbenzonitrile;2-chloro-4-(5-hydroxy-3-methoxy-5-(trifluoromethyl)-3a, ...

METHOD AND DEVICE FOR THE DETECTION OF MOLECULAR INTERACTIONS

The present invention relates to devices and methods for the detection of analytes. In particular, the invention relates to methods for the qualitative and/or quantitative detection of analytes, comprising a microarray on a substrate, onto which probe molecules are immobilized on array elements, said microarray being disposed on a first surface of the device; and a detection chamber formed between the first surface including the microarray disposed thereon and a second surface, wherein the distance between the microarray and the second surface is variable, and wherein the second surface has a displacement structure. 1. Device for the qualitative and/or quantitative detection of analytes , comprising:a) a micro array on a substrate, onto which probe molecules are immobilized on array elements, said microarray being disposed on a first surface of the device; andb) a detection chamber formed between the first surface including the micro array disposed thereon and a second surface, wherein the distance between the micro array and the second surface is variable, and wherein the second surface has a displacement structure.268-. (canceled)69. Device according to claim 1 , wherein the displacement structure is located on the side of the second surface that is facing the microarray.70. Device according to claim 69 , wherein the displacement structure is located on the side of the second surface that is facing the micro array in such a way that claim 69 , when the reaction chamber is in a compressed state claim 69 , it is located at least partially opposite the surface of the micro array.71. Device according to claim 1 , wherein the displacement structure claim 1 , when viewed from the first surface claim 1 , has a convex shape.72. Device according to claim 1 , wherein the detection chamber comprises at least two sub-chambers claim 1 , wherein in a first non-compressed state the sub-chambers are in fluid connection claim 1 , and in a second compressed state there is no fluid ...

Spirohydantoin compounds and their use as selective androgen receptor modulators

The present invention relates to a compound of formula (I-1) in free form or in pharmaceutically acceptable salt form 9. A compound according to in free form or in pharmaceutically acceptable salt form which is selected from2-chloro-4-(6-hydroxy-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-3-methyl-4-(1-methyl-2,4,6-trioxo-1,3-diazaspiro[4.4]nonan-3-yl)benzonitrile;2-chloro-4-(4,6-dihydroxy-1-methyl-2-oxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-4-(1-ethyl-6-hydroxy-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-4-(6-fluoro-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-3-methyl-4-(1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]non-6-en-3-yl)benzonitrile;2-chloro-4-(6-hydroxy-1-methyl-2-oxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-3-methyl-4-(1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)benzonitrile;2-chloro-4-(1-(2-methoxyethyl)-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-4-(1-ethyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-4-(6-hydroxy-2,4-dioxo-1-oxa-3-azaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-4-(6-hydroxy-4-methoxy-2-oxo-1-oxa-3-azaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-3-methyl-4-(2-oxo-1-oxa-3-azaspiro[4.4]non-6-en-3-yl)benzonitrile;2-chloro-4-(7-hydroxy-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-4-(7-fluoro-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-3-methyl-4-(1-methyl-2,4,7-trioxo-1,3-diazaspiro[4.4]nonan-3-yl)benzonitrile;2-chloro-4-(7,7-difluoro-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-4-(6-(hydroxymethyl)-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methylbenzonitrile;2-chloro-4-(1,6-dimethyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-3-methyl benzonitrile;2-chloro-4-(4-imino-1-methyl-2-oxo-1,3-diazaspiro[4.4]nonan-3-yl)-3- ...

ZERO DOWNTIME FOR FREQUENT SOFTWARE UPDATES

In order to perform relatively frequent, zero-downtime software updates, a bridge schema corresponding to an original schema of a database system may be generated. Within the bridge schema, a plurality of views corresponding to a plurality of database tables of an application executing on an application server may be generated. A connection from the application to the original schema may be changed to the bridge schema, to thereby continue executing the application using the plurality of views. When a change file defining update changes to at least one original database table of the plurality of database tables is received, content of the at least one original database table may be synchronized with a target table reflecting the update changes. Then, the connection may be changed back to the original database schema to continue executing the software application, using the plurality of database tables and including the target table. 1. A computer program product , the computer program product being tangibly embodied on a non-transitory computer-readable storage medium and comprising instructions that , when executed , are configured to cause at least one computing device to:generate a bridge schema corresponding to an original schema of a database system, the original schema including a plurality of database tables and having a connection to an application server and being used by a software application executing on the application server;generate, within the bridge schema, a plurality of views corresponding to the plurality of database tables;change the connection to the bridge schema and continue executing the software application using the plurality of views;receive a change file defining update changes to at least one original database table of the plurality of database tables;synchronize content of the at least one original database table with a target table, the target table reflecting the update changes; andchange the connection back to the original database ...

AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 2. The compound according to or a pharmaceutically acceptable salt thereof wherein claim 1 ,{'sub': '1', 'Ris chloro or methyl; and'}{'sub': 2', '2', '5', '6, 'Ris SONRR.'}3. The compound according to or a pharmaceutically acceptable salt thereof wherein{'sub': '5', 'Ris H or methyl; and'}{'sub': 6', '4', '6', '7, 'Ris C-Ccycloalkyl optionally substituted once or more than once with R; and'}{'sub': 7', '1', '3', '1', '3', '1', '3, 'Ris independently selected from hydroxyl, haloC-Calkyl, halogen, and C-Calkyl, hydroxyC-Calkyl.'}4. The compound according to or a pharmaceutically acceptable salt thereof wherein{'sub': 5', '6', '8, 'Rand Rtogether with the N atom to which they are attached form a 4-, 5- or 6-membered heterocyclic non-aromatic ring optionally comprising one additional heteroatom selected from N, O or S, said ring being optionally substituted once or more than once with R; and'}{'sub': 8', '1', '3, 'Ris independently selected from halogen and hydroxyC-Calkyl.'}5. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sub': '1', 'Ris chloro or methyl;'}{'sub': 2', '2', '3, 'Ris NHSOR; and'}{'sub': 3', '4, 'Ris selected from phenyl optionally substituted once or more than once with R;'}{'sub': 3', '6, 'and C-Ccycloalkyl optionally substituted with hydroxyl.'}6. The compound according to or a pharmaceutically acceptable salt thereof claim 5 , wherein{'sub': 4', '1', '3', '1', '3', '1', '3, 'Ris independently selected from halogen, C-Calkoxy, cyano, C-Calkyl, hydroxyl, and haloC-Calkyl; or'}{'sub': 4', '3, 'two Rat adjacent carbon atoms form a 5- or 6-membered heterocyclic non-aromatic ring comprising at ...

BENZOTHIAZOLONE COMPOUND

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form 4. A process according to wherein the LG is chloro. The present invention relates to a benzothiazolone compound, to its preparation, to its medical use as a beta-2 adrenoceptor agonist and to medicaments, pharmaceutical compositions and combinations comprising it.Benzothiazolone compounds which are beta-2-adrenoceptor agonists are described in WO2004/16601 and WO2006/056471. WO2005/110990 also describes benzo-condensed heterocycles as beta-2 agonists.While beta-2 agonists have long been known for their bronchodilating properties, they are also known for their capability to produce skeletal muscle hypertrophy.Numerous studies have focused on therapeutic applications of the anabolic properties of beta-2 agonists for ameliorating muscle wasting and improving muscle function. However, this class of compounds has also been associated with undesirable side-effects, including increased risk of adverse cardiovascular-related events. Thus, the use of beta-2 agonists in muscle wasting diseases has hitherto been limited by cardiac hypertrophy and potentially deleterious effects on cardiovascular function.There is a need to provide new beta-2 agonists that are good drug candidates. In particular, a new beta-2 agonist should bind potently to the beta-2 adrenoceptor whilst showing little affinity for other receptors, such as e.g. the beta-1 adrenoceptor, the alpha-1A adrenoceptor, or the 5HTreceptor, and show functional activity as an agonist. It should be metabolically stable and possess favourable pharmacokinetic properties. It should be non-toxic and demonstrate few side-effects, in particular fewer cardiac side-effects than known marketed beta-2 agonists, such as e.g. formoterol. Furthermore, the ideal drug candidate will exist in a physical form that is stable, non-hygroscopic and easily formulated.The compound of the invention is a selective beta-2 agonist. In ...

Pyridinone derivatives and their use as selective ALK-2 inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 4. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '1', 'Ris hydrogen.'}5. The compound according to or a pharmaceutically acceptable salt thereof wherein{'sup': 2', '3, 'sub': '1-6', 'Rand Rindependently represent hydrogen or Calkyl.'}6. The compound according to or a pharmaceutically acceptable salt thereof wherein{'sup': 2', '3, 'Rand Rare both methyl.'}7. The compound according to or a pharmaceutically acceptable salt thereof wherein{'sup': '4', 'Ris hydrogen.'}8. The compound according to or a pharmaceutically acceptable salt thereof whereinX is —CH.9. The compound according to or a pharmaceutically acceptable salt thereof wherein{'sup': 6', '7, 'Rand Rindependently represent hydrogen or fluorine.'}10. The compound according to or a pharmaceutically acceptable salt thereof wherein{'sup': '8', 'sub': '1-6', 'Ris hydrogen or Calkyl.'}11. The compound according to or a pharmaceutically acceptable salt thereof whereinY is —CH.12. The compound according to or a pharmaceutically acceptable salt thereof whereinW is —C(═O)—.14. The compound according to or a pharmaceutically acceptable salt thereof which is selected from the group consisting of5-(5-(1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-1-methylindolin-2-one;5-(1′-Isopropyl-5′-methoxy-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-1-methylindolin-2-one;5-(5-(1-Isopropyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridin-3-yl)-1-methylindolin-2-one;1-methyl-5-(6′-oxo-1′-(pentan-3-yl)-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)indolin-2-one;5-(5′-Ethyl-1′-isopropyl-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-1-methylindolin-2-one;5-(1′-Cyclobutyl-6′-oxo-1′,6′-dihydro-[3,3 ...

METHODS FOR DETECTING MULTIPLE NUCLEIC ACIDS IN A SAMPLE USING REPORTER COMPOUNDS AND BINDING MEMBERS THEREOF

The present invention relates to methods for determining the presence and/or amount of multiple nucleic acids in a sample. 135-. (canceled)36. A method of determining the presence and/or amount of nucleic acids in a sample , comprising an amount of a first nucleic acid;', 'an amount of a second nucleic acid;', 'an amount of a FRET compound capable of forming complexes with the first nucleic acid, wherein the FRET compound comprises a binding portion specific to a region of the first nucleic acid and a first detectable label that has, in an uncomplexed state, a first detectable characteristic and, in a complexed state, a second detectable characteristic that differs from the first detectable characteristic;', 'an amount of a reporter compound capable of forming complexes with the second nucleic acid, wherein each reporter compound comprises a binding portion specific to a region of the second nucleic acid and a second detectable label; and', 'a binding member capable of capturing the reporter compound, wherein forming of complexes of the second nucleic acid with the reporter compound inhibits capturing of the reporter compound by the binding member;, '(a) providing'}(b) subjecting the first and/or second nucleic acid to amplification;(c) forming complexes each comprising a first nucleic acid and a FRET compound;(d) forming complexes of a subset of the amount of reporter compound with a second nucleic acid;(e) capturing a remaining subset of the amount of reporter compound not in complex with a second nucleic acid on the binding member;(f) determining a value indicative for the presence and/or amount of first nucleic acid captured by FRET compounds; and(g) determining a value indicative for the presence and/or amount of reporter compound captured on the binding member.37. The method of claim 36 , further comprising determining a value indicative for the presence and/or amount of second nucleic acid based on the value indicative for the presence and/or amount of ...

Aminopyridine derivatives and their use as selective alk-2 inhibitors

Method and device for the detection of molecular interactions

The invention relates to devices and methods for the detection of specific interactions between probe and target molecules. In particular, the invention relates to methods for the qualitative and/or quantitative detection of targets, including: introducing a sample containing targets into a reaction chamber formed between a first surface of the device and a second surface of a device, which is preferably located opposite to the first surface, wherein the distance between the first and the second surface is variable; and detecting the targets.

Assays for measuring nucleic acids

A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative for the presence and/or amount of the target molecules, a microfluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the microfluidic network.

Methods for virus detection

AZA-INDAZOLE COMPOUNDS USEFUL IN INJURIES OF TENDONS AND / OR LIGAMENTS

<p>La presente invención proporciona un compuesto de formula (I) en forma libre o en forma de sal farmacéuticamente aceptable. Los compuestos de la invención son útiles en el tratamiento de las lesiones de tendones y ligamentos, en particular en la reparación de tendones y ligamentos.</p> <p>ESPACIO PARA FÓRMULA</p> <p> </p> <p> </p> <p> The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form. The compounds of the invention are useful in the treatment of tendon and ligament injuries, in particular in the repair of tendons and ligaments. </p> <p> SPACE FOR FORMULA </p> <p> </p> < p> </p>

Benzothiazolone compound

BENZOTHEIZOLONE UNION

Η παρούσα εφεύρεση παρέχει μία ένωση με τον τύπο (I) σε ελεύθερη μορφή ή στη μορφή (I) ενός φαρμακευτικώς αποδεκτού άλατος, μία μέθοδο για τη βιομηχανική παραγωγή της ένωσης της εφεύρεσης και τις θεραπευτικές της χρήσεις. Η παρούσα εφεύρεση περαιτέρω παρέχει ένα συνδυασμό φαρμακολογικώς δραστικών παραγόντων και φαρμακευτικές συνθέσεις. The present invention provides a compound of formula (I) in free form or in the form (I) of a pharmaceutically acceptable salt, a method for the industrial production of the compound of the invention and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

DEVICE AND METHOD

Device and process for binding assays

Method and device for the detection of molecular interactions

The present invention relates to devices and methods for the detection of analytes. In particular, the invention relates to methods for the qualitative and/or quantitative detection of analytes, comprising a microarray on a substrate, onto which probe molecules are immobilized on array elements, said microarray being disposed on a first surface of the device; and a detection chamber formed between the first surface including the microarray disposed thereon and a second surface, wherein the distance between the microarray and the second surface is variable, and wherein the second surface has a displacement structure.

Benzothiazolone compound

Blister Pack With Radio-Frequency Identification Device, and Method For Manufacturing Same

The invention specifies a blister pack ( 1 ) with a radio-frequency identification device ( 2, 2′ ) which comprises—a support body ( 3 ) which is made of flat plastic material and which has a plurality of depressions ( 5 ), produced from deforming this material, within a planar region ( 4 ) for the purpose of holding the packed goods,—an aluminium sealing foil ( 7 ) which is connected flat to the planar region ( 4 ) of the support body ( 3 ), and—a radio-frequency identification device ( 2, 2′ ) which is fitted in the region ( 8 ) of the support body ( 3 ) which projects over the aluminium sealing foil ( 7 ).

Electrical powered weight and fullness level system

A collection apparatus weight and fullness level reporting system includes: an inlet; a removable collection bin receiving material placed into the collection apparatus; a compacting mechanism including a ram body, wherein the ram body travels between a home position located above the collection bin to a maximum travel position located inside the collection bin, wherein during each compaction cycle the ram body travels along a variable length of the compaction path; a fullness-reporting module that determines the height of the material in the collection bin; and a controller that determines the length of the compaction path the ram body travels during each compaction cycle based on the input received from the fullness reporting module, wherein at the end of each compaction cycle in which the material height is below a maximum height, the ram body is brought to rest at a height below the home position.

Benzothiazolone compound

AZA-INDAZOLE COMPOUNDS FOR USE IN INJURIES OF TENDONS AND / OR LIGAMENTS

La presente invención proporciona un compuesto de fórmula (I) en forma libre o en forma de sal farmacéuticamente aceptable (I) un método para la elaboración de los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.

Indazole compounds for use in tendon and/or ligament injuries

Device for holding and detecting substance libraries

The invention relates to a holding device for substance libraries which can be used, more particularly, for the detection of target molecules with the aid substance libraries. Said device comprises: (i) a holder (101) for a substance library carrier; (ii) a substance library carrier (104) which can be fixed to the holder (101); (iii) a detection surface (107) applied to the substance library carrier (104) whereon a substance library is immobilised. At least the substance library carrier (104) can be introduced into a laboratory reaction tube.

Benzothiazolone compound

BENZOTIAZOLONA COMPOSITE

La presente invención proporciona un compuesto de la fórmula (I) en forma libre o en forma de una sal farmacéuticamente aceptable un método para fabricar el compuesto de la invención, y sus usos terapéuticos. La presente invención proporciona además una combinación de agentes farmacológicamente activos y composiciones farmacéuticas.

Aminopyridine derivatives and their use as selective alk-2 inhibitors.

La invención se refiere a un compuesto de la fórmula (I) en forma libre o en forma de sal farmacéuticamente aceptable (I), a composiciones farmacéuticas que comprenden dicho compuesto y al uso de dicho compuesto en el tratamiento de osificación heterotópica y fibrodisplasia osificante progresiva. (Ver Fórmula).

DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS SELECTIVE INHIBITORS OF ALK-2

La presente solicitud se relaciona con un compuesto en forma libre o en forma de sal farmacéuticamente aceptable, a composiciones farmacéuticas que comprenden dicho compuesto y al uso de dicho compuesto en el tratamiento de la osificación heterotópica y fibrodisplasia osificante progresiva. Reivindicación 1: Un compuesto de la fórmula (1) en forma libre ó en forma de sal farmacéuticamente aceptable, en donde L es un enlace, (CH₂)ₙ, -CH(CH₃)-, -O-(CH₂)ₙ-, -C(O)-, -C(O)-NH-(CH₂)ₙ-; n es 1, 2, 3; R¹ se selecciona de cicloalquilo C₃₋₇ opcionalmente sustituido una vez o más de una vez con un sustituyente seleccionado independientemente entre hidroxilo, halógeno, alquilo C₁₋₃; cicloalquilo C₅₋₁₀ puenteado sustituido opcionalmente una vez o más de una vez con un sustituyente seleccionado independientemente entre hidroxilo, hidroxialquilo C₁₋₃; R² y R³ se seleccionan independientemente de H, halógeno, alquilo C₁₋₃; R⁴ es un anillo heterocíclico no aromático que contiene N, que comprende opcionalmente uno o más heteroátomos adicionales seleccionados de N, O ó S, en donde dicho anillo está opcionalmente sustituido una vez o más de una vez con R⁷; R⁷ se selecciona independientemente de alquilo C₁₋₃, hidroxialquilo C₁₋₃, haloalquilo C₁₋₃, alcoxi C₁₋₃alquilo C₁₋₃, haloalcoxi C₁₋₃alquilo C₁₋₃, alquinilo C₂₋₄, cianoalquilo C₁₋₃, (CH₂)ₘ-R⁸; m es 0, 1, 2 ó 3; R⁸ se selecciona a partir de un anillo heterocíclico no aromático saturado o insaturado de 4, 5 ó 6 miembros que comprende uno o más heteroátomos seleccionados de N, O ó S, dicho anillo opcionalmente sustituido una vez o más de una vez con un sustituyente seleccionado independientemente de oxo, SO₂-alquilo C₁₋₃, haloalquilo C₁₋₃; o un cicloalquilo C₃₋₆ opcionalmente sustituido una vez o más de una vez con halo. The present application relates to a compound in free form or in the form of a pharmaceutically acceptable salt, to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of ...

Benzothiazolone compound

The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

BENZOTIAZOLONA COMPOUNDS

La presente invención proporciona un compuesto de la fórmula (I) en forma libre o en forma de una sal farmacéuticamente aceptable

COMPOUNDS DERIVED FROM PYRIDIN-2-ONA (6´-OXO-1´, 6´DIHYDRO) SUBSTITUTED AS SELECTIVE INHIBITORS OF ALK-2

<p>La invención se refiere a compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos de Fórmula I,</p> <p>ESPACIO PARA FÓRMULA</p> <p>útiles como inhibidores selectivos de ALK-2.</p> <p> The invention relates to substituted pyridin-2-one (6'-oxo-1 ', 6'dihydro) derivatives of Formula I, </p> <p> SPACE FOR FORMULA </p> <p > useful as selective ALK-2 inhibitors. </p>

Suitcase or bag with a one-handed openable lid element

Ein Koffer oder eine Tasche (1) mit einem durch Wandelemente (6a, 6b, 8, 10) sowie einem Bodenelement (4) definierten Grundkörper (2) zur Aufnahme von Utensilien, der eine Öffnung (12) umfasst, die durch ein am Grundkörper (2) aufgenommenes, aus einer Freigabeposition in eine Schließposition bewegbares Deckelelement (14) verschließbar ist, zeichnet sich dadurch aus, dass das Deckelelement (14) einteilig und eigensteif ausgestaltet ist und aus seiner Schließposition über am Grundkörper (2) sowie am Deckelelement (14) angeordnete zusammenwirkende Führungselemente (16a, 16b, 18, 20) durch eine kombinierte Schwenk- und Verschiebebewegung in die Freigabeposition bewegbar ist. A suitcase or bag (1) having a basic body (2) for receiving utensils defined by wall elements (6a, 6b, 8, 10) and a bottom element (4) and comprising an opening (12) passing through the base body (2) recorded, from a release position in a closed position movable cover element (14) is characterized in that the cover element (14) is designed in one piece and intrinsically stiff and from its closed position on the base body (2) and on the cover element (14 ) arranged cooperating guide elements (16a, 16b, 18, 20) is movable by a combined pivoting and sliding movement in the release position.

Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions

The use of compound of formula I in the preparation of a medicament, e.g. for the treatment of condition mediated by CCR3.

Organic compounds

The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R1, R2, Ar, A and B are defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

Spirohydantoin compounds and their use as selective androgen receptor modulators

The present invention relates to a compound of formula (1-1 ) in free form or in pharmaceutically acceptable salt form in which the substituents are as defined in the specification; to its preparation, to its use as a medicament and to medicaments comprising it. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Indazole compounds for use in tendon and/or ligament injuries

Device and method for detecting molecular interactions

The invention relates to devices and methods for detecting specific interactions between target and probe molecules. In particular, the invention relates to a device for qualitatively and/or quantitatively detecting molecular interactions between probe and target molecules, comprising: a) a micro-array on a substrate onto which probe molecules are immobilized on array elements, said micro-array being disposed on a first surface of the device; and b) a reaction chamber formed between the first surface including the micro-array disposed thereon, and a second surface, the distance between said micro-array and the second surface being variable.

SUBSTRATE OF PAINTED PAPER AND PROCEDURE FOR MANUFACTURING.

Sustrato de papel pintado para un papel pintado desprendible en seco con una extensión mínima en estado húmedo, consistente en una tira de varias capas con una cara inferior que da a la pared cuando el papel pintado está en uso y una cara superior que da a la habitación cuando el papel pintado está en uso, entre las cuales está dispuesta en la dirección desde la cara inferior a la cara superior una capa inferior fibrosa, compuesta por una mezcla de fibras basadas en celulosa y fibras sintéticas, y una capa superior fibrosa, formada por una mezcla de fibras basadas en celulosa libre de fibras sintéticas, caracterizado porque la capa inferior y la capa superior están fieltradas entre sí por prensado húmedo y la cara superior está satinada de tal modo que es imprimible por impresión directa, en particular por huecograbado en la como máximo falta 1 punto por cm 2 . Wallpaper substrate for a dry removable wallpaper with a minimum extension in the wet state, consisting of a strip of several layers with a lower face that faces the wall when the wallpaper is in use and an upper face that gives the room when the wallpaper is in use, between which a fibrous bottom layer, composed of a mixture of cellulose-based fibers and synthetic fibers, and a fibrous top layer, formed in the direction from the bottom face to the top face is arranged by a mixture of cellulose-based fibers free of synthetic fibers, characterized in that the lower layer and the upper layer are felted together by wet pressing and the upper face is satin such that it is printable by direct printing, in particular by gravure printing. The maximum is 1 point per cm 2.

Machine readable diagnostic test devices and methods and apparatus to make and/or process the same

Methods, apparatus, systems, and articles of manufacture to make and/or process a diagnostic test device are disclosed. An example apparatus includes a sensor to measure a current between a first electrode and a second electrode of a bioelectrochemical cell coupled to a test zone corresponding to a target analyte on a porous media of a device; a processor to compare the current to a threshold; and when the current is more than the threshold, identify that the target analyte is present in a sample; and an antenna to wirelessly transmit results.

Case or Bag Having a Lid Element That can be Opened With one Hand

A case or bag for holding items has a basic body that is defined by wall elements and a floor element. The basic body has opening that can be closed by a lid element that is disposed on the basic body and can be moved out of an open position into a closed position. The lid element is configured in one piece and with inherent rigidity and can be moved out of its closed position into the open position by interacting guide elements disposed on the basic body and on the lid element through a combined pivoting and displacing movement.

Rolling bearing for a shaft

A rolling bearing for a shaft that has a cylindrical peripheral surface, the bearing comprising a race (12) to be fitted onto the shaft, and rolling bodies (16) arranged to roll on the race (12), characterized in that the race (12) has a polygonal internal cross-section, so that it engages the peripheral surface of the shaft only in the vicinity of the center of each side (28) of the polygon.

Device and method for the detection of particles

The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or the second surface. The invention also relates to corresponding methods for the detection of particles, comprising positioning a sample supposed to comprise one or more species of particles to be detected in a reaction chamber, displacing at least a part of the sample within the reaction chamber via the one or more displacers; and detecting/determining a value indicative for the presence and/or number of one or more species of particles.

Use of fused imidazole derivatives to mediate ccr3 related conditions

The use of compound of formula (I) in the preparation of a medicament , e.g, for the treatment of condition mediated by CCR 3.

aminopyridine derivatives and their use as selective alk-2 inhibitors

patente de invenção: "derivados de aminopiridina e seu uso como inibidores seletivos de alk-2". a invenção refere-se a um composto de fórmula (i) em forma livre ou em forma de sal farmaceuticamente aceitável (i) para as composições farmacêuticas contendo o referido composto e ao uso do referido composto no tratamento da ossificação heterotópica e fibrodisplasia ossificante progressiva. "Aminopyridine derivatives and their use as selective alk-2 inhibitors". The invention relates to a compound of formula (I) in free or pharmaceutically acceptable salt form (I) for pharmaceutical compositions containing said compound and the use of said compound in the treatment of heterotopic ossification and progressive ossifying fibrodysplasia.

BENZOTIAZOLONA COMPOSITE

La presente invención proporciona un compuesto de la fórmula( I) en forma libre o en forma de una sal farmacéuticamente aceptable, Un método para fabricar el compuesto de la invención, y sus usos terapéuticos. La presente invención proporciona además una combinación de agentes farmacológicamente activos y composiciones farmacéuticas. The present invention provides a compound of the formula (I) in free form or in the form of a pharmaceutically acceptable salt, a method of manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.

Pyridinone derivatives and their use as selective alk-2 inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Wallpaper substrate and method for the production thereof

Der Erfindung, die ein Tapetensubstrat für eine trocken abziehbare Tapete mit minimaler Nassdehnung aus einer mehrschichtigen Bahn mit einer Unterseite und einer Oberseite, zwischen denen eine faserige untere Lage aus einem Faserstoffgemisch auf Zellulosebasis und Synthesefasern und eine faserige obere Lage aus einem synthesefaserfreien Faserstoffgemisch auf Zellulosebasis angeordnet ist, und ein Verfahren zur Herstellung eines solches Tapetensubstrates betrifft, liegt die Aufgabe zugrunde, ein nahezu fehlerfreies Bedrucken der Oberseite in guter Qualität insbesondere mittels Direktdruck zu ermöglichen und das kostengünstig herstellbar ist. Dabei soll insbesondere eine Bedruckbarkeit dadurch erreicht werden, dass die Anzahl an Fehlstellen im Ausdruck minimiert wird. Gelöst wird dies dadurch, dass die untere Lage und die obere Lage durch Gautschen miteinander verfilzt sind, und die Oberseite satiniert und für durch Direktdruck, insbesondere für Tiefdruck, direkt bedruckbar ausgebildet ist.

Aminopyridine derivatives and their use as selective alk-2 inhibitors

The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form HH2N N R H R R1' N 0R3 R 5 (1) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Aminopyridine derivatives and their use as selective alk-2 inhibitors.

La invención se refiere a un compuesto de la fórmula (I) en forma libre o en forma de sal farmacéuticamente aceptable (I), a composiciones farmacéuticas que comprenden dicho compuesto y al uso de dicho compuesto en el tratamiento de osificación heterotópica y fibrodisplasia osificante progresiva. (ver Fórmula).

Benzothiazolone compound

Capillary suction evaporation device

The invention relates to: a capillary suction evaporation device for utilising the capillary action of a fluid and for converting potential energy into electrical energy; and a method for operating the capillary suction evaporation device, wherein the capillary action and electromagnetic radiation are utilised in order to impart a higher potential energy to a fluid which is then converted into electrical energy.

Laser welded enclosure for electronics, circuitry or sensors

An enclosure is shown, comprising at least a first substrate and a second substrate, wherein the first substrate is transparent at least in part and/or at least for a wavelength bandwidth, at least one common laser weld zone wherein material of the first and second substrates is mixed, wherein the laser weld zone is designed such to permanently join the first substrate to the second substrate and/or to provide for a hermetic sealing between the first substrate and the second substrate, at least one function zone, for example comprising a cavity, enclosed inside the enclosure, and at least one fluid channel allowing for a fluid flow between said function zone and an outside.

Blisterpackung mit radiofrequenz- identifikationseinrichtung sowie verfahren zu deren herstellung

Tapetensubstrat und verfahren zu seiner herstellung

Verfahren und vorrichtung zum nachweis molekularer wechselwirkungen